Crotedumab
- CAS No.
- 1452387-69-7
- Chemical Name:
- Crotedumab
- Synonyms
- REGN1193;Crotedumab;Crotedumab (anti-GCGR);Research Grade Crotedumab;Research Grade Crotedumab(DHE51802)
- CBNumber:
- CB28080972
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 4JQ68PW6XF |
Crotedumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0621501 | Crotedumab 99.22% | 1452387-69-7 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0621501 | Crotedumab 99.22% | 1452387-69-7 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0621501 | Crotedumab 99.22% | 1452387-69-7 | 10mg | $1354 | 2026-06-04 | Buy |
| aablocks | AA029KZ1 | Crotedumab ≥95%(SDS-PAGE&SEC-HPLC) | 1452387-69-7 | 1mg | $560 | 2026-06-02 | Buy |
| aablocks | AA029KZ1 | Crotedumab ≥95%(SDS-PAGE&SEC-HPLC) | 1452387-69-7 | 5mg | $1480 | 2026-06-02 | Buy |
Crotedumab Chemical Properties,Uses,Production
Uses
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes[1][2].
in vivo
Crotedumab (3-30 mg/kg; s.c. once weekly for 4 weeks) reduces blood glucose and body weight and induces reversible hyperglucagonemia and α-cell hyperplasia in DIO C57BL/6 mice[2].
Crotedumab (10 mg/kg; a single s.c.) markedly decreases blood glucose for 18 days in diabetic ob/ob mice[2].
REGN1193 (20 mg/kg; a single i.v.) produces a robust reduction in overnight-fasted blood glucose in both the conscious and anesthetized state of diabetic cynomolgus monkeys as well as in blood glucose measured 1 hour after feeding[2].
| Animal Model: | Diet-induced obese (DIO) male C57BL/6NTac mice were maintained on high-fat diet[2] |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | S.c. injection once weekly for 4 weeks |
| Result: | Markedly reduced blood glucose throughout the dosing period. Reversibly decreased body weight during the dosing period. Dose- and time-dependently increased glucagon and GLP-1. Reversibly increased α-cell area. |
References
[1] Kostic A, et, al. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. DOI:10.1111/dom.13075
[2] Okamot H, et, al. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Endocrinology. 2015 Aug;156(8):2781-94. DOI:10.1210/en.2015-1011
Crotedumab Preparation Products And Raw materials
Raw materials
Preparation Products
Crotedumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
